Leukemia, Myelodysplasia, Transplantation
Conference Coverage
PI3Kδ/γ inhibitor generates rapid responses in CLL
VIENNA—New research indicates that duvelisib, a dual inhibitor of PI3Kδ and PI3Kγ, can generate rapid partial responses in treatment-naïve...
Clinical Review
Chronic Myeloid Leukemia
News
Radiation increases risk of death from CML, other leukemias
power plant in Germany Protracted exposure to ionizing radiation, even at low doses, can increase a person’s risk of dying from certain leukemias...
Conference Coverage
‘Radically different’ PI3Kδ inhibitor lacks hepatotoxicity
Photo by Larry Young LUGANO—Updated phase 1 results with TGR-1202 suggest this next-generation PI3kδ inhibitor lacks the hepatotoxicity associated...
News
P13K inhibitors TGR-1202, duvelisib found clinically active in CLL
Key clinical point: The investigational P13K inhibitors TGR-1202 and duvelisib were clinically active in phase I trials. Major finding: TGR-1202...
Conference Coverage
Advanced age no barrier to continuous myeloma regimen
Key clinical point: Patients over age 75 draw the same survival benefit with continuous lenalidomide plus low-dose dexamethasone over MPT as their...
News
Approach could build bridge to HSCT in T-PLL
Photo by Chad McNeeley A treatment approach that combines epigenetics and immunotherapy could provide a bridge to transplant in patients with T-...
Conference Coverage
Nivolumab produces ‘dramatic’ responses in HL
Photo courtesy of UCLA LUGANO—The PD-1 checkpoint inhibitor nivolumab produces rapid, durable, and, in some cases, “dramatic” responses in...
News
Inactivating an enzyme can eradicate T-ALL
Preclinical research suggests that inactivating a single enzyme could eradicate or prevent T-cell acute lymphoblastic leukemia (T-ALL). The...
Feature
Cardiovascular disease in oncology
News
New insight into blood production
in the bone marrow Scientists say they have identified a family of multipotent progenitor (MPP) cells that are the first to arise from...